A plain-language guide

Pompe disease

What is known, what is still uncertain, and what is actively debated, written plainly, and built only from published medical research.

Early map · 7 sourced statements Every statement names its source Updated 2026-06-12
Please read this first. This guide is a companion to your medical team, not a replacement, and it is not medical advice. Everything here is tied to published research. If something you expected is not here, it almost always means we have not mapped a source for it yet, not that it is unknown to medicine. Pompe disease is an early, growing map, so it will look incomplete on purpose: we would rather show less and have every line be something you can check than fill the page with claims we cannot stand behind. For anything about your own situation, your clinicians hold the full picture. How this guide is built and why.

What it is

Pompe disease (glycogen storage disease type II) is an inherited condition caused by deficiency of the enzyme acid alpha-glucosidase (GAA), so glycogen builds up in muscle and other tissues.

Signs and symptoms

Cardiomegaly

In the severe infantile form, the heart muscle thickens and the heart becomes enlarged early in life.

Limited evidenceSource: OMIM:232300
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:41718282
Notesplain_language confirmed from PMID:41718282 via curation 2026-06-12.
Last reviewed2026-06-12

Autosomal recessive inheritance

Pompe disease is inherited in an autosomal recessive pattern, needing a changed copy of the GAA gene from each parent.

Limited evidenceSource: OMIM:232300
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:42131243
Notesplain_language confirmed from PMID:42131243 via curation 2026-06-12.
Last reviewed2026-06-12

Proximal muscle weakness

Weakness of the muscles closest to the trunk (proximal muscle weakness) is a core feature, alongside weakening of the muscles used for breathing.

Limited evidenceSource: OMIM:232300
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:42135804
Notesplain_language confirmed from PMID:42135804 via curation 2026-06-12.
Last reviewed2026-06-12

Muscle weakness

Muscle weakness is a defining feature and, in infants, can come with feeding difficulties.

Limited evidenceSource: OMIM:232300
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:42135242
Notesplain_language confirmed from PMID:42135242 via curation 2026-06-12.
Last reviewed2026-06-12

Treatment and management

What the research describes, not a recommendation. Treatment decisions belong with your clinician.

This covers treatments that appear in the published research mapped here. Investigational and experimental therapies are not included, so their absence is a boundary of this map, not a sign they do not exist.

Alglucosidase alfa

Alglucosidase alfa is an enzyme replacement therapy that supplies the missing GAA enzyme and is the main treatment for Pompe disease.

Used to help with: Glycogen storage disease II.

Limited evidenceSource: PMID:41718282
The source text this rests on
“- Source: Short-Term Intensive Avalglucosidase Alfa Regimen in Late-Diagnosed Infantile Pompe Disease: A Case Report. - Source ID / type: PMID:41718282 / peer_reviewed_study - Publication date: 2026 - Study design: Case Reports, Journal Article Sample size: ## Finding Background and Clinical Significance: Classic infantile-onset Pompe disease (IOPD) is the most severe form of Pompe disease, manifesting within the first months of life with hypertrophic cardiomyopathy and severe hypotonia.”
An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.
Evidence ratingweak
Confidence (0-1)0.7
Replicationunreplicated
Notesconfirmed from PMID:41718282 via curation 2026-06-12
Last reviewed2026-06-12

Turn this into questions for your doctor

The hardest part is often knowing what to ask. PatientLead Health helps families turn what is on this page into the right questions for their care team.

Prepare for your appointment with PatientLead Health →

How to read the evidence labels

Widely acceptedSpecialists broadly agree on this.
Strong evidenceBacked by solid, repeated research.
Moderate evidenceReasonable evidence, still being confirmed.
Limited evidenceSome evidence, but not yet convincing.
Early evidenceAn early finding that needs more study.
Experts disagreeResearchers actively disagree about this.

Where this comes from

This guide is built from 2 published source(s). Every claim above links back to one of them. Click any source ID to read the original on PubMed.

OMIM:232300 · Orphanet/HPO annotations for Glycogen storage disease II
PMID:41718282 · Short-Term Intensive Avalglucosidase Alfa Regimen in Late-Diagnosed Infantile Pompe Disease: A Case Report.